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Acquired drug resistance is a frequent challenge in breast cancer. A tumor may 
initially respond to chemotherapy, but later become resistant and relapse. This is largely 
due to intra-tumoral heterogeneity; tumor genetic subclones with higher fitness in 
response to chemotherapy survive, and the patient’s cancer becomes drug-resistant. In 
additional, non-genetic phenotypic alterations in response to chemotherapy may promote 
drug resistance. How breast cancers evolve to become drug-resistant is unclear. A better 
understanding of how this occurs could lead to alternative therapeutic regimens to treat 
drug-resistant breast cancer or prevent its development. To address this problem, we 
performed genomic and phenotypic analysis of four breast cancers through 2 to 15 years 
of diverse treatments, using a unique set of longitudinal samples from these patients. This 
revealed genetic events likely leading to drug resistance, including acquisition of BRCA2 
reversions and ABCB1 fusions. Further, cancer phenotypes evolved dramatically after 
treatment, including increased post-treatment mesenchymal, receptor tyrosine kinase, and 
immune avoidance gene expression profiles. In one patient, treatment of cultured patient 
cells with drugs targeting the receptor tyrosine kinase phenotype was more effective in 
post-treatment, receptor tyrosine kinase-high cells compared to the pre-treatment cells. 
Thus, we have identified both mutations and phenotypes that may promote breast cancer 
drug resistance, some of which may be targeted to treat drug-resistant cancers.  
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 Cancers arise from somatic mutations leading to unrestrained proliferation. They 
are genetically unstable due to harboring loss-of-function mutations in DNA repair  
pathways or other mechanisms1. This genomic instability leads to continuous evolution,  
even after the cancer has already been established. Each cell division, mutations occur;  
occasionally, these mutations lead to a selective advantage, and cells with the mutation  
out-compete neighboring cells until a cancer subclone (a single-cell-derived genetic  
lineage of cancer cells comprising a substantial proportion of cancer cells in the body) is  
established. Some mutations provide a selective advantage in the face of drug treatment,  
thus promoting acquired cancer drug resistance2. These mutations may or may not 
provide a selective advantage under normal conditions, but after treatment may come to 
dominate the cancer cell population as other non-resistant subclones die during initial 
response to the drug. A better understanding of which mutations promote drug resistance 
in cancer could lead to more effective therapeutic options.  
The mutations promoting acquired drug resistance in breast cancer are imperfectly 
understood. One study found that few commonly occurring mutations occurred after 




treatment3. Other studies have identified drug resistance-promoting mutations appearing 
in cultured breast cancer cells after long-term exposure to chemotherapy4. However, it is 
unclear whether these drug resistance mechanisms occur in actual patients, which 
motivated us to study pre- and post-treatment breast cancers directly from patients to 
identify possible mutations promoting drug resistance using DNA sequencing (DNA-
Seq). Further, the few studies that have analyzed pre- and post-treatment breast cancers 
have explored each breast cancer’s evolution after one treatment regimen3, rather than 
tracking their sequential evolution through multiple regimens.  
In addition to acquired mutations, drug-resistant cancers may acquire biological 
phenotypes promoting drug resistance2. These phenotypes may not be caused by any one 
obvious drug resistance mutation, but may nevertheless suggest therapeutic 
vulnerabilities. Thus, we sought to study both the genetic evolution (largely through 
DNA-Seq) and phenotypic evolution (largely through RNA-Seq) of breast cancers before 
and after multiple successive treatments. This led to the identification of both genetic 
events (Chapter 2) and phenotypes (Chapter 3) appearing post-treatment in breast 
cancers, which suggested treatment options, including one treatment option which we 







GENETIC EVOLUTION OF FOUR BREAST CANCERS 
 
Introduction  
 An understanding of the genetic evolution of breast cancers after treatment may 
suggest alternative treatment options for drug-resistant breast cancer. Thus, we studied 
the genetic evolution of four breast cancers over 2-15 years, during which all classes of 
breast cancer treatments were administered.  
 
Materials and Methods 
Overview 
 We performed DNA-Seq (whole-genome sequencing or WGS) on 2-6 
longitudinal breast cancer samples from each of four patients, as well as their germline 
(blood-derived) samples. The acquisition of multiple longitudinal samples from the same 
patient, which is difficult and rare due to concerns and morbidities from repeated biopsy, 
was facilitated by using metastatic pleural effusion and ascites fluids from patients. 
Pleural effusions are fluid build-up in the pleura, a space surrounding the lungs, due to 
metastatic cancer cell infiltration5. Ascites are similar but occur in the peritoneal cavity6. 
Some 10-15% of breast cancer patients have pleural and/or ascitic metastasis5, but these 




In contrast to tumor biopsies, which hold inherent risks and discomforts, drainage of 
these cancer cell-rich chest and abdominal fluids is relatively safe and desirable for the 
patient, for whom the fluid buildup can be extremely uncomfortable5. Some patients 
required frequent, even weekly, drainage, enabling the tracking of their cancer’s 
evolution with good resolution.  
 In addition to identifying potential drug resistance mutations, WGS can help with 
identification of the general subclone evolution of each patient’s cancer. This is because 
each subclone tends to have dozens, if not hundreds, of mutations that evolve in a similar 
direction as a tell-tale indicator of that subclone’s evolution. For example, a group of 
mutations appearing after treatment with a modal variant allele frequency (VAF; percent 
of sequencing reads with the mutation) of 0.5 indicates a new, completely dominant 
subclone representing 100% of the cells (since most mutations are heterozygous, a VAF 
of 0.5 generally indicates a heterozygous present in all cells). On the other hand, a group 
of mutations appearing after treatment with a modal VAF of 0.3 indicates a new subclone 
representing 60% cellular prevalence. DNA-Seq of individual cells can be used to verify 
findings thus inferred. Below, I describe detailed methodology for isolating cancer 
samples, performing DNA-Seq, determining mutational subclone evolution, and 
performing related experiments on samples from our four breast cancer patients.  
 
Samples and processing 
Breast cancer samples were obtained from malignant pleural effusions or ascites 
(or FFPE in one case). After fluid drainage, cells were pelleted at 3,750 RPM for 5 




and incubated at 37 °C for 5 minutes, followed by centrifugation, which was repeated 
until red blood cells were absent from pellet. Cells were washed thrice with PBS and 
frozen in 90% FBS with 10% DMSO. The patient #2 day 1320 pleural effusion had 
cancerous chunks from which DNA or RNA was isolated directly. For scRNA-Seq of this 
sample, minced chunks were dissociated in Renaissance medium (Cellaria) with 1% 
TrypLE (Life Technologies) and 1 U/μL DNase I and 2 mg/mL collagenase (Roche) for 
20 minutes at 37 °C (shaking occasionally), followed by 10 minutes in a Biomaster 80 
(Seward) and passing chunks through a 21-gauge syringe, and freezing in 10% DMSO 
for storage until scRNA-Seq. 
  
DNA isolation and sequencing 
Frozen vials of pleural effusion or ascites cells were thawed, and cells were 
pelleted to remove DMSO in supernatant and re-suspended in buffer as described in 
Miltenyi OctoMACS and QuadroMACS instructions. CD45+ white blood cells were 
depleted from non-tumor-chunk samples (most samples) using the Miltenyi OctoMACS 
magnetic separation system with MS columns or the QuadroMACS magnetic system 
with LD columns along with anti-CD45 microbeads from Miltenyi. Germline DNA was 
obtained from PBMCs from each patient or by sorting for CD45+ white blood cells from 
pleural effusions. DNA was isolated using Qiagen’s QIAamp DNA Micro Kit, or for 
FFPE, the QIAamp DNA FFPE Tissue Kit. Whole-exome sequencing (WES) was 
performed at the Huntsman Cancer Institute’s High Throughput Genomics Core Facility 
(HCI) using the Agilent SureSelect QXT Human All Exon v5 + UTRs kit and library 




Whole-genome sequencing (WGS) was performed at the McDonnell Genome Institute at 
Washington University, NantOmics, or HCI using the Illumina TruSeq Nano DNA 
Library Prep Kit or PCR-free library prep and an Illumina HiSeq 2500 or X instrument 
with paired-end sequencing.  
 
Single-cell DNA sequencing 
Frozen viable pleural effusion or ascites vials were thawed and CD45+ white 
blood cells were depleted using Miltenyi’s QuadroMACS. Individual cells were captured 
using Fluidigm C1 chips (10-17 μm cell diameter); whole-genome amplification was 
performed per manufacturer’s instructions. Targeted amplification of mutation-containing 
regions was performed using Fluidigm Access Array and BioMark instruments per 
manufacturer’s instructions. Libraries were sequenced on Illumina MiSeq. Reads were 
aligned to hg19 with BWA MEM v0.7.8. Variants were called using MuTect v1.1.4. Co-
occurrence of mutations (at least 1 mutant read) in individual cells was evaluated using 
Fisher’s exact test. Single cells with more than one subclone-defining mutation are 
shown. 
 
Whole-exome sequencing variant identification 
Read quality was verified using FastQC and reads were trimmed using 
Trimmomatic8 v0.32 (http://www.usadellab.org/cms/index.php?page=trimmomatic). 
Alignment to hg19 was done with BWA MEM9 v0.7.8 (https://github.com/lh3/bwa). 
BAM files were refined using PicardTools’ MarkDuplicates and FixMateInformation 




RealignerTargetCreator, IndelRealigner, and BaseRecalibrator (v3.2-2; 
https://www.broadinstitute.org/gatk/download/). WES somatic SNVs were called with 
MuTect12 v1.1.4 (https://www.broadinstitute.org/cancer/cga/mutect) and annotated with 
Oncotator13 v1.3.0.0 (https://github.com/broadinstitute/oncotator). CNVs were called 
from WES using VarScan14 v2.3.7 (http://dkoboldt.github.io/varscan) copynumber and 
copyCaller, from pileups generated by SAMTools, to determine copy-number 2 genes for 
SubcloneSeeker. Segmentation was done with DNAcopy in R. Segmented data were 
converted to gene level using UCSC’s refGene.txt (hg19) annotation. Log2 fold-change 
values were converted to absolute copy using 2n+1 where n is log2 fold-change from 
diploid. CNV values were shifted in each sample to make the 2-copy peak centered at 2 
and multiplied around the 2-axis to maximize number of genes near (within 0.1) of 1, 3, 
and 4 (to adjust for normal contamination).  
 
Whole-genome sequencing variant identification 
WGS DNA sequences were aligned to hg19 using BWA MEM using SpeedSeq15. 
SNVs and indels variants were identified using FreeBayes 
(http://arxiv.org/abs/1207.3907) on each of the four breast cancer patients analyzed. 
Variants were annotated using SnpEff16 and variants with quality below 5 were excluded. 
Somatic mutations were identified using “somatics” 
(https://github.com/brentp/gobio/tree/master/somatics). As a secondary variant calling 
approach, we used VarScan somatic. This revealed the APC and BRCA2 K817* 
mutations in patient #4 not detected by FreeBayes; all other small variants discussed were 




Structural variants were detected from WGS as follows. We used 
SAMBLASTER17 v0.1.22 to extract discordant paired-end reads and split reads. 
LUMPY18 v0.2.12, or LUMPY within the SpeedSeq suite (sv utility), was used to call 
structural variants based on these reads, followed by SVTYPER15 (v0.0.2) to determine 
VAFs for each variant. Somatic variants were identified as with FreeBayes variants. 
Variants were annotated with BEDTOOLS19 v2.25.0-12-g7f765bc. Variants with quality 
less than 400 were excluded, except for patient #2 ABCB1 fusions, which did not meet 
quality thresholds but were included due to corroborating identification in RNA-Seq data. 
Circos20 plots were made from FreeBayes, LUMPY, and CNV analysis. Circos plots 
show evolving mutations (going from VAF below 0.05 to 0.05 or above for small 
mutations and a threshold of 0.075 for structural) in color and background variants in 
grey; Cancer Gene Census21 genes are shown by name, while other mutations are 
indicated by tick marks. Copy number variation (CNV) was determined from WGS data 
using VarScan as described for WES. For Circos plots CNV tracks, 30-segment window 
averages (absolute copy) were plotted after adjustment for normal contamination.  
 
Correction for normal contamination 
Variant allele frequencies (VAFs) for WGS FreeBayes-identified somatic variants 
were corrected for normal contamination by determining tumor purity using CNV data. 
Absolute copy of each gene was determined using VarScan and DNAcopy in R as 
described in previous sections. Perfectly pure tumor samples have a large copy peak at 2 
and smaller peaks at 1, 3, and 4, while normal-contaminated samples have a profile 




the 2-axis using a range of multipliers until the maximum number of genes possible fell 
within 0.1 of 1, 3, and 4. The multiplier thus obtained was used to calculate tumor purity 
(= 1.0 / multiplier), and VAFs for FreeBayes somatic mutations were multiplied by the 
sample’s multiplier to obtain adjusted VAF. VAFs used and reported are all adjusted 
except for the germline BRCA2 germline V643fs mutation VAFs in patient #4 given its 
presence in both normal and cancer cells. 
 
Identification of evolution clusters and subclones from WGS data 
Clusters of co-evolving mutations were identified from the WGS SNV and indel 
data (after normal contamination correction) by clustering copy-neutral (absolute copy 
1.5-2.5 or, in the case of pseudo-tetraploid patient #2, between 3.6-4.4) mutations based 
on the samples in which they were present (at variant allele frequency of at least 0.05). 
Consensus VAFs for each mutation cluster were determined using kernel density 
estimation in R; cellular prevalences for each cluster were then obtained by multiplying 
these values by 2 (or 4 for pseudo-tetraploid patient #2). In some cases, two peaks were 
present, indicating different sub-clusters and possibly additional subclones. Mutation 
clusters with the most mutations were incorporated into subclone analysis. Subclone 
structures were then determined using cellular prevalences thus calculated, using rules 
described elsewhere22. For patient #1, an additional subclone was made apparent from 
deeper WES and single-cell DNA sequencing (purple mutations) that was not detectable 






Identification of subclones using SubcloneSeeker 
We started with diploid, missense SNVs identified from deep WES by MuTect 
for patient #1 to corroborate WGS-based subclone findings. These variants were then 
subjected to Affinity Propagation Clustering23 (via R package apclust (https://cran.r-
project.org/web/packages/apcluster/citation.html)), with similarity calculated via 
expSimMat(r=2, w=0.1), to identify groups of variants that share similar VAFs across all 
samples. We then performed subclone structure reconstructions at adjacent pairwise time-
points through the pairwise joint analysis capability of SubcloneSeeker22, and manually 
merged structures into a longitudinal evolution history, abiding to the same evolutionary 
consistency rule implemented in pairwise merging. 
 
Mutational signatures 
Mutational signatures were identified for WGS SNVs by first determining the 
trinucleotide sequence around SNV mutation sites, with the mutation site in the center, 
using an in-house script. For trinucleotides starting with an A or G, the reverse 
complement was used to minimize the number of mutation contexts as reported 
previously24. From these data, we identified the percent of mutations that fell into each 
trinucleotide and transition/transversion pattern. 
  
TopHat Fusion 
TopHat25 v2.0.6 (http://ccb.jhu.edu/software/tophat/index.shtml) was run on bulk 
RNA-Seq data using hg19 followed by TopHat-Fusion Post26. This identified the 




patient #2, which we identified manually by searching for reads fusing the 3’ end of 
ABCB1 exon 2 with transcripts aligning elsewhere (Blast).  
 
qRT-PCR 
HCC70 cells grown in DMEM/F12 with 9% FBS were treated for 24 hours with 
indicated doses of paclitaxel, followed by RNA isolation with RNAzol, reverse 
transcription with SuperScript III Reverse Transcriptase (Life Technologies), and qPCR 
using KAPA SYBR FAST with primers to APOBEC3B or ACTB. Data were analyzed 
using ΔΔCt to obtain ACTB-normalized APOBEC3B mRNA expression.  
 
DNA content measurement 
Frozen viable pleural effusions were thawed and washed. Cells were resuspended 
in 4% paraformaldehyde in PBS and fixed 15 minutes. Cells were pelleted and 
resuspended in 5 mL PBS for 15 minutes. Cells were pelleted and resuspended in staining 
buffer (2% FBS in PBS). 3 µM DAPI was added and incubated 15 minutes. Cells were 
washed twice in PBS and resuspended in PBS, followed by flow cytometry. 
 
Results and Discussion 
We used a systems approach to determine the genetic and phenotypic evolution of 
four metastatic ER+ breast cancers over 2 to 15 years and 3 to 6 samples per patient.  For 
each patient, we determined subclonal evolution through bulk and/or single-cell DNA 
sequencing at various points in the patient’s treatment history (Fig. 1, #1 and #2). Further, 





Figure 1 | Overview of systems approach for identifying therapeutic vulnerabilities 
from longitudinal genomic analysis. * = resistant subclone. Made in conjunction with 




















subclones, and to identify drugs predicted to target them (covered in Chapter 3). This 
identified effective treatments for post-chemotherapy subclones, as shown by drug assays 
using patient tumor cells (Fig. 1; #3 and #4).  
To determine the subclonal evolution of our four breast cancers, we used 60× 
whole-genome (WGS), 100× whole-exome (WES), and targeted single-cell DNA 
sequencing, along with the SubcloneSeeker22 tool. First, somatic WGS mutations found 
in copy-neutral regions were grouped into mutation clusters based on their presence or 
absence at specific timepoints. Next, the cellular prevalence of each mutation cluster was 
determined by identifying the variant allele frequency of maximum density at each 
timepoint, and subclones were then identified using rules previously described22. For 
patient #1, this approach was validated by SubcloneSeeker analysis of WES data 
(Supplementary Fig. 1) and refined by single-cell DNA or RNA sequencing, which 
confirmed SubcloneSeeker predictions and refined subclone identification 
(Supplementary Fig. 2). (See Materials and Methods.) Subclones are represented as 
circles containing mutation clusters (smaller colored circles within subclones) in Fig. 2, 
with cellular prevalence of each subclone indicated as a percentage next to each subclone. 
In addition, variant allele frequencies for copy-neutral mutations (SNVs and indels) used 
to determine subclone evolution are shown as a heatmap to the left of each subclone 
schematic in Fig. 2. Copy-number and structural variants for each patient are shown in 
Circos plots in Supplementary Fig. 3. Mutations in “cancer genes” according to the  
Cancer Gene Census27 are shown by name in Fig. 2 and in Supplementary Fig. 3. 
Patient #1 (ER+/HER2+) samples were collected over more than 2 years from 




Figure 2 | Subclonal evolution of four breast cancers over 2-4 years. (a-d) Subclonal 
evolution of breast cancer patients #1 to #4 through treatment. Left side shows variant 
allele frequencies of copy-neutral somatic mutations (WGS) organized into clusters, with 
relevant cancer-associated mutations (may or may not be copy-neutral or somatic) 
indicated. Right shows subclone evolution. Subclones are indicated by large circles; 
mutation clusters are indicated by small colored circles. Relevant mutations in subclones 
are indicated by text or boxed insets. Cellular prevalence is indicated as percent next to 
subclone. Tax, paclitaxel; trast, trastuzumab; dox, doxorubicin; cb, carboplatin; gem, 
gemcitabine; cap, capecitabine; exem, exemestane; vinorel, vinorelbine; fulv, fulvestrant; 










after the following treatments: (1) paclitaxel and trastuzumab followed by docetaxel, (2) 
liposomal doxorubicin, (3) trastuzumab and MM-111 (an experimental HER2/HER3 
antagonist28) followed by (4) carboplatin and gemcitabine (Fig. 2a), after which the 
patient succumbed to disease. Background (ubiquitous) mutations in patient #1 included a 
germline BRCA2 E1493fs mutation that underwent loss of heterozygosity in her cancer, 
an ESR1 L538P (likely activating29) mutation, and large homozygous structural variants 
(likely inactivating) in SMAD4 and MAP2K4 (Fig. 2a, Supplementary Fig. 3a). Following 
a response to paclitaxel with trastuzumab, the patient acquired three new subclones, 
suggesting independent acquired resistance mechanisms to this treatment (“tax + trast”; 
see Fig. 2a). One of these subclones, SC2, appeared at a low cellular prevalence after 
paclitaxel and trastuzumab (<1%) but came to dominate at 100% cellular prevalence after 
subsequent treatment with liposomal doxorubicin (“doxorubicin” in Fig. 2a), to which the 
patient partially responded. This bottleneck subclone possessed an SLC25A40-ABCB1 
fusion resulting from a structural deletion on chromosome 7, which fused the active 
promoter and 5’ UTR of SLC25A40 to the ABCB1 gene, preserving the entire ABCB1 
coding region and leading to increased levels of the ABCB14 drug efflux pump (Fig. 2a, 
inset and Supplementary Figs. 4, 5a). SC2 likewise possessed a copy gain on 
chromosome 10, including CDK1, and copy loss on chromosome 2 (Supplementary Fig. 
3a, blue arrows). In addition, the bottleneck subclone SC2 possessed 1,047 new SNVs 
and indels (“bottleneck mutations” in Fig. 2a, left; dark-orange mutation circles found in 
Fig. 2a, right), including mutations in the cancer-associated genes NR4A330 and 
FANCD231. 




APOBEC-associated24 mutations after paclitaxel and trastuzumab (subclone SC1; Fig. 2a, 
Supplementary Fig. 6, third column), with 31.3% of subclone-specific SNVs in this 
subclone being APOBEC-associated compared to 10.0% of subclone-specific variants in 
its parental subclone (light-blue mutations in Fig. 2a), and 12.7% of background (grey) 
variants (Supplementary Fig. 6, first and second columns). This mutational process may 
have been promoted by the patient’s taxane treatment as paclitaxel increased APOBEC3B 
expression in vitro (Supplementary Fig. 7). Thus mutational processes may differ 
between subclones within a tumor and may be promoted by certain treatments. 
Patient #2 (ER+/HER2+) was followed for over 3 years, including 6 pleural 
effusions.  Samples were obtained before, during, or after the following treatments: (1) 
capecitabine, (2) exemestane, (3) exemestane and everolimus, (4) vinorelbine, (5) 
carboplatin and gemcitabine, (6) fulvestrant, (7) liposomal doxorubicin, (8) paclitaxel, (9) 
Abraxane, and (10) eribulin (Fig. 2b). This patient was pseudo-tetraploid (Supplementary 
Fig. 8) due to an early genome doubling event, necessitating some modifications to 
subclone identification (see Materials and Methods) and making it unclear whether 
subclone SC4 was derived from SC3 and SC3’s prevalence (Fig. 2b). Patient #2 
possessed a germline heterozygous BRCA2 E49* mutation that underwent loss of 
heterozygosity in the patient’s cancer, and a possibly oncogenic FLT4 E766D somatic 
mutation, at all timepoints. This patient initially possessed one major subclone (SC3) 
with less than 80% cellular prevalence (Fig. 2b). Towards the end of treatment with the 
anti-estrogen exemestane, a new minor subclone (SC4), with 10% cellular prevalence, 
appeared possessing an ESR1 D540G mutation (Fig. 2b, Supplementary Fig. 3b), which 




requiring treatment with a wide variety of therapies. After more than 2 years and 
numerous treatment regimens, patient #2’s cancer was dominated by a new subclone 
(SC5), derived from the ESR1-mutant subclone SC4, at 100% cellular prevalence (Fig. 
2b). The new bottleneck subclone SC5 possessed 936 new SNVs and indels (“bottleneck 
mutations” in Fig. 2b heatmap). One of these, an in-frame BRCA2 A47-P59 deletion, 
removed the inactivating frameshift in one copy of BRCA2 and likely restored its 
function, as a resistance mechanism to platinum therapy32 the patient had received (Fig. 
2b, “BRCA2 reversion” inset, and Supplementary Fig. 9a).  Additionally, SC5 acquired 
two ABCB1 fusions (PTK2-ABCB1 and AFF3-ABCB1) that, like the SLC25A40-ABCB1 
fusion, each provided ABCB1 with a strong promoter while maintaining the entire 
ABCB1 coding region intact (Fig, 2b, bottom-right inset and Supplementary Fig. 10), and 
apparently promoted ABCB1 expression (Supplementary Fig. 5b). These fusions may 
have promoted resistance to doxorubicin and paclitaxel. It is unclear whether the two 
fusions were acquired sequentially due to selective pressure for additional ABCB1 
expression, or co-existed in the original refractory subclone. Subclone SC5 also lost a 
large region of chromosome 20q, including the tumor suppressor GNAS (Supplementary 
Fig. 3b, orange arrow). Unlike patient #1, this patient’s mutational signatures, such as the 
APOBEC signature, were relatively uniform between subclones (Supplementary Fig. 6). 
Patient #3 (ER+/HER2-) was followed for more than 3 years, including 3 pleural 
effusions. Samples were obtained before, during, or after: (1) two doxorubicin courses, 
(2) letrozole, and (3) exemestane (Fig. 2c). The patient showed clinical benefit from each 
of these treatments followed by progression. Background mutations included two 




two subclones existed: SC6, enriched in C>T mutations, dominated at 73% cellular 
prevalence, while subclone SC7 represented 19% of cells (Fig. 2c, Supplementary Fig. 
6). However, after doxorubicin, letrozole, and exemestane treatment, a new SC7-derived 
subclone came to dominate at 100% cellular prevalence (SC8; Fig. 2c, Supplementary 
Fig. 3c). This bottleneck subclone possessed a striking 5,540 additional SNVs and indels 
(Fig. 2c, “bottleneck mutations”), nearly three times the background mutation number (n 
= 2,042). Of the new SNVs, 67.4% were APOBEC-associated, compared to 27.5% of 
background (grey) SNVs (Fig. 2c, Supplementary Fig. 6). Among the 5,540 new 
mutations in SC8 were ESR1 Y539N, which likely promoted resistance to letrozole or 
exemestane anti-estrogen treatments29, APC V1822D, and CDH1 (E-cadherin) R154T 
mutations (Fig. 2c, Supplementary Fig. 3c). Additionally, the bottleneck subclone SC8 
gained copies of chromosome 5p, and lost regions of chromosome 1p, a tumor-
suppressive region34,35, 2q, 15, and 22 (Supplementary Fig. 3c, green arrows). Lost 
regions included the apoptosis genes CASP8, CASP10, and BID36, loss of which could 
prevent apoptosis. 
Patient #4 (ER+/HER2-) was followed for 15 years, including her primary tumor 
(ductal carcinoma in situ or DCIS) and recurrent pleural effusions, including the 
following treatments: (1) doxorubicin with cyclophosphamide (“AC” in Fig. 2d), (2) the 
anti-estrogens tamoxifen and letrozole, with a period of capecitabine between, (3) 
cisplatin followed by fulvestrant, interferon treatment for a non-cancer diagnosis, 
carboplatin, then tamoxifen (“platinum/anti-ER”), and (4) paclitaxel followed by olaparib 
(“tax/olaparib”; Fig. 2d). Background mutations in patient #4 included a BRCA2 V643fs 




independent cancers at ~50% cellular prevalence each, with independent BRCA2 second-
hit mutations: a BRCA2 K817* mutation, which subsequently disappeared; and a BRCA2 
V2620fs mutation, representing the surviving subclone giving rise to subsequent samples 
(Fig. 2d, Supplementary Fig. 3d). Thirteen years later, after transition from DCIS to 
metastatic disease, the patient had acquired additional mutations in TP53 (G279E 
homozygous), PTEN (L302fs and N329fs), MAP2K4 (G183fs homozygous), and 
TGFBR2 (G68S); these may have promoted transition from DCIS to metastatic cancer. 
At this first metastatic timepoint (day 4970), there were two major subclones, SC9 (20% 
cellular prevalence) and SC10 (80%). Subsequently, the patient received platinum-based 
therapy (cisplatin and carboplatin), which selected for a subclone of SC10, SC11, with a 
BRCA2 reversion (L638fs) restoring the frame of the V643fs mutation after only a few 
aberrant amino acids, likely restoring BRCA2 function (Fig. 2d, bottom-right inset and 
Supplementary Fig. 9b). After further treatment with paclitaxel and olaparib, the BRCA2-
revertant subclone SC11 decreased from 52% to 8% cellular prevalence, while SC12 
became dominant at 74%. BRCA2 reversions are thought to also promote olaparib 
resistance37; thus, it is unclear why SC11 decreased in prevalence after olaparib. One 
potential explanation is that subclone SC12, which survived olaparib, may have acquired 
a direct reversion of the germline BRCA2 V643fs mutation, as the V643fs variant allele 
frequency went down to 0.28 at day 5586 from an average of 0.51 in all other samples, 
including germline (Supplementary Fig. 11). In addition, patient #4’s DCIS-to-metastatic 
conversion was accompanied by enrichment in APOBEC-associated mutations, while 
SC12 was also enriched in APOBEC mutations, and SC11 had enrichment in a pair of 




While each patient’s subclone evolution differed, several themes emerged. First, 
effective treatments resulting in long-term cancer control generally resulted in genetic 
bottleneck events in which one major subclone survived treatment (subclones SC2, SC5, 
and SC8). Second, two patients acquired ABCB1 promoter fusions previously unreported 
in breast cancer, likely promoting drug resistance. Third, BRCA2 reversion events may be 
common in platinum-treated BRCA2 carriers, and can occur through multiple 
mechanisms. Lastly, mutational signatures substantially differed between subclones, 
which may affect clonal fitness. Such mutational signatures can apparently be acquired 
de novo, independent of the parent subclone’s mutational processes, and may be drug-
induced (Supplementary Figs. 6, 7). 
These data suggest that targeting ABCB1 and BRCA2 reversions, perhaps in 
combination with standard chemotherapy, may overcome drug resistance. Targeting the 
ABCB1 protein directly has led to toxicities due to ABCB1’s essential function in the 
blood-brain barrier38 and protection of stem cells39. However, one alternative approach 
might be to target the fused promoter driving ABCB1 mRNA expression by inhibiting 
transcription factors essential for transcription initiation from that promoter. This could 
be done by identifying small molecules that inhibit the expression of the native gene of 
the promoter (SLC25A40, PTK2, or AFF3) using an approach such as the Connectivity 
Map40. This approach could lead to less toxicity if inhibiting expression of the fusion 

















Supplementary Figure 1 | Possible subclonal evolution structures identified by 
SubcloneSeeker for breast cancer patient #1. (a) Variant allele frequencies for coding, 
diploid mutations identified from exome sequencing. Mutation clusters (C1-C9), 
identified by Affinity Propagation Clustering, are indicated by colors. (b-d) Possible 
subclonal evolution structures identified through analysis of mutations in (a) with 
SubcloneSeeker. Cellular prevalences are indicated next to each subclone. (b) and (c) 
were found to be consistent with single-cell sequencing while (d) was not. RS7 indicates 
resistant (bottleneck) subclone from cluster C7. Used with permission of Yi Qiao, Gabor 














Supplementary Figure 2 | Single-cell sequencing of pre-doxorubicin cells in breast 
cancer patient #1. Left, bulk variant allele frequencies of mutations increasing after 
taxane therapy studied by single-cell sequencing as determined by bulk whole-exome 
sequencing (WES). Middle, results of single-cell sequencing of pre-dox cells (day 305), 
with each column representing a single cell, mutations sequenced indicated by the name 
of the gene (or nearby gene) mutated, and mutations indicated by filled squares; mutation 
clusters identified in Supplementary Fig. 1 are also indicated. Right, co-occurrence 
analysis of mutations in single cells; edges indicated p < 0.05 by Fisher’s exact test. 








Supplementary Figure 3 | SNV, structural variant, and CNV evolution in four 
breast cancers. (a-d) Circos plots showing mutation evolution of breast cancer patients 
#1 to #4 through treatment. Each circle represents chromosomes 1 through X (clockwise 
from top) arranged in a circle. Protein-coding somatic SNVs and indels are indicated 
outside each circle as ticks or, for Cancer Gene Census genes, by name. Structural 
variants (large deletions, translocations, inversions, and duplications) are indicated inside 
each circle as a line joining the start and end of the variant, with Cancer Gene Census 
gene mutations indicated outside. Copy number changes are represented in the grey 
region with higher copy towards the outer edge. Newly appearing SNVs, indels, and 
structural variants are shown in color, while selected newly appearing CNVs are 
indicated by colored arrows. CNVs were not determined in the patient #4 day 0 sample 






Supplementary Figure 4 | Identification of SLC25A40-ABCB1 fusion in patient #1 
after doxorubicin. (a) Structure of SLC25A40-ABCB1 per WGS (left) and variant allele 
frequencies over time for the SLC25A40-ABCB1 fusion (right) in patient #1. (b) 
Schematic of split RNA-Seq reads from post-doxorubicin (day 732) sample. (c) Inferred 
SLC25A40-ABCB1 fusion transcript (left) and number of RNA-Seq reads (reads spanning 





Supplementary Figure 5 | Evolution of ABCB1 expression in three breast cancer 
patients. ABCB1 RPKM (RNA-Seq) for patients #1 (a), #2 (b), and #3 (c) over time with 
drug treatment indicated in grey. See Fig. 2 legend for drug abbreviations. Made in 






Supplementary Figure 6 | Mutation signature evolution in four breast cancers.  
Heatmap showing percent of SNVs in each subclone, defined in Fig. 2, with each of 96 






Supplementary Figure 7 | Paclitaxel promotes APOBEC3B expression. HCC70 cells 
were treated 24 hours at indicated doses, followed by qRT-PCR. APOBEC3B expression 





Supplementary Figure 8 | Patient #2 breast cancer is pseudo-tetraploid. Copy 
number relative to germline for each gene was plotted on a histogram for example 
samples from patients #1 (a), #2 (b), and #3 (c). Inferred absolute copy is indicated with 
asterisks by peaks. (d) Flow cytometry was performed on example samples from patients 





Supplementary Figure 9 | BRCA2 reversions after platinum treatment in two breast 
cancer patients. Schematics showing mutation status of BRCA2 in patients #2 (a) and #4 
(b). BRCA2 protein domain structure is from N- (left) to C-terminus (right), with 
mutations indicated as red arrows. Copy number for BRCA2 was inferred as described in 






Supplementary Figure 10 | Identification of AFF3-ABCB1 and PTK2-ABCB1 fusions 
in patient #2 after treatment. (a) Structure of AFF3-ABCB1 and PTK2-ABCB1 fusions 
per WGS (left) and their variant allele frequencies over time (right) in patient #2. (b) 
Schematic of split RNA-Seq reads from post-bottleneck (day 1320) sample. Reverse 
complements of anti-sense reads are shown for clarity. (c) Inferred AFF3-ABCB1 and 
PTK2-ABCB1 fusion transcripts (left) and number of RNA-Seq reads (split reads) 







Supplementary Figure 11 | Possible direct BRCA2 reversion in patient #4 at last 
timepoint. Variant allele frequencies of patient #4 BRCA2 germline mutation (V643fs) 

















PHENOTYPIC EVOLUTION OF FOUR BREAST CANCERS 
AND ALTERNATIVE TREATMENTS 
 
Introduction 
Just as understanding the genetic evolution of breast cancer after treatment can 
suggest treatment options for drug-resistant diseases, elucidating the phenotypic 
evolution of breast cancers after treatment may suggest alternative treatment options for 
drug-resistant breast cancer2. Further, phenotypic evolution patterns may indicate 
treatments when no clear drug resistance mutation is identified. Thus, we studied the 
phenotypic evolution of four breast cancers using both bulk and single-cell RNA-Seq. 
Based on these data, we identified an effective drug combination in drug-resistant patient 
cells from one patient.  
 
Materials and Methods 
RNA isolation from samples 
Cancer samples were obtained and normal cells were depleted as described in the  
Materials and Methods section of Chapter 2. RNA was isolated using Qiagen RNeasy 




mRNA Sample Prep with oligo dT selection or TruSeq Stranded Total RNA Sample Prep 
Kit with RiboZero Gold library prep and Illumina HiSeq. 
 
RNA-Seq data processing 
RNA-Seq data were processed with Rsubread41,42 v1.16.1 
(https://bioconductor.org/packages/release/bioc/html/Rsubread.html) in R using only 
uniquely mapped reads and the Hamming distance to break ties. The maximum indels 
allowed per alignment was 5. Gene-level expression values were processed to RPKM 
(bulk RNA-Seq) or TPM (scRNA-Seq).  
 
Proliferation index 
QC-passed reads were aligned to hg19 using MapSplice43. Alignment profile was 
determined by Picard Tools v1.64 (http://broadinstitute.github.io/picard/).  Aligned reads 
were sorted and indexed using SAMtools and translated to transcriptome coordinates then 
filtered using UBU v1.0 (https://github.com/mozack/ubu). Transcript abundance 
estimates for each sample were performed using RSEM44 using the UCSC knownGene 
transcript and gene definitions. Raw RSEM read counts for all RNA-Seq samples were 
normalized to the overall upper quartile45.  Log2 transformed gene expression estimates 
were analyzed using the PAM50 algorithm46 after gene-level adjustments estimated from 







Pathway predictions using ASSIGN 
Pathways signatures were first developed by overexpressing IGF-1R, EGFR, K-
Ras G12V, c-Raf, Bad, myr-Akt, or GFP control in human mammary epithelial cells 
(HMECs) grown in MEBM (Lonza) using adenovirus48. RNA-Seq data and additional 
methods describing the generation of the signatures can be found on GEO at GSE73628. 
RNA-Seq data were adjusted for batch effects using ComBat49. Differentially expressed 
gene lists for each pathway were selected using ASSIGN50 Bayesian gene selection. Gene 
lists were then used to estimate pathway activity in each of the breast cancer patient 
samples analyzed. Molecular Signatures Database gene lists were also used as ASSIGN 
input in some cases.  
 
Single-cell RNA-Seq 
Frozen viable patient pleural effusions were thawed and CD45+ white blood cells, 
and in some cases fibroblasts (Anti-Fibroblast Microbeads, Miltenyi), were depleted 
using quadroMACS (Miltenyi). Cells were loaded into a Fluidigm C1 or C1 HT single-
cell mRNA-seq chip (for 10-17 µm cell diameter), and single-cell libraries were prepared 
per manufacturer’s instructions. Illumina paired-end sequencing was performed and data 
were processed to TPM using Rsubread. Cells expressing fewer than 1,700 genes or with 
fewer than 150,000 mapped reads were excluded. CNV was inferred from scRNA-Seq 
using the approach described elsewhere51,52. Normal human mammary epithelial cells on 
which scRNA-Seq was performed using Fluidigm C1 were used as the normal (2-copy) 
state. Mutations were called from scRNA-Seq data by identifying cells with at least 2 




possessed CNVs associated with specific subclones, and in the case of patient #1, we 
verified and refined this based on presence or absence of subclone-defining point 
mutations in scRNA-Seq. CNVs partially present pre-treatment, and increased post-
treatment (i.e. going from absolute copy 2.2 to 3.0), were assumed to belong to the 
surviving subclone, while those partly present pre-treatment that disappeared were 
assumed to represent disappearing subclones. Cells were assigned to either survivor or 
disappearing subclones based on these CNVs. Violin plots of scRNA-Seq ssGSEA scores 
and TPM were generated with Seurat in R53.  
 
Heatmaps 
RTK heatmaps were generated by adding minimum non-zero RTK RPKM 
expression value to each RTK and calculating log2 fold change from day 0. Heatmap was 
generated in R (ComplexHeatmap). 
  
ssGSEA 
ssGSEA was run using GSVA v1.14.1 in R54 
(https://www.bioconductor.org/packages/release/bioc/html/GSVA.html) using RNA-Seq 
RPKM (bulk) or TPM (single-cell) values and Molecular Signatures Database C2 
signatures and custom signatures described. To identify gene sets changing most 
dramatically in bulk RNA-Seq data, we determined the maximum absolute value change 
between consecutive timepoint pairs in any patient for each signature. Full EMT 






HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION; immune signatures 
are PHONG_TNF_TARGETS_UP and 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION; proliferation signatures 
are REACTOME_UNWINDING_OF_DNA, 
REACTOME_G1_S_SPECIFIC_TRANSCRIPTION57, 
SA_REG_CASCADE_OF_CYCLIN_EXPR, KALMA_E2F1_TARGETS58, and 
KONG_E2F3_TARGETS59. Our custom anti-apoptosis gene set consisted of the 6 anti-
apoptotic Bcl-2 family members60 BCL2, BCL2L1, BCL2L2, MCL1, and BCL2A1, and 
the 8 inhibitors of apoptosis (IAP) family members61 NAIP, BIRC2, BIRC3, XIAP, 
BIRC5, BIRC6, BIRC7, and BIRC8. The all-58 RTKs signature was assembled from a 
review62. ASSIGN was used to verify and improve interpretation of evolving signatures 
identified using ssGSEA. 
 
Western blots 
Western blots were performed by scraping cells in cold PBS and lysing pelleted 
cells in lysis buffer (5 mM EDTA, 150 mM NaCl, 50 mM Tris, pH 8.0, 1% Triton X-100, 
and 0.1% SDS with protease and phosphatase inhibitor cocktails from Sigma) for 15 
minutes on ice. Cleared diluted supernatants were boiled in Laemmli buffer 10 minutes 
and 20-30 μg of protein per lane was run by SDS-PAGE and transferred to PVDF 
membrane. Western blot on untreated patient #1 cells was done on never-passaged cells, 
while elacridar-treated cells were passage 4. For Western blots of patient cells, cells were 





Patient #1 never-cultured pleural effusion or ascites cells were plated at ~3,000 
cells/well in 384-well black plates with clear bottom in Renaissance medium (Cellaria) 
with 5% FBS, 25 ng/mL cholera toxin (Sigma), and 1% antibiotic/antimycotic (Life 
Technologies); to this was added 20% filtered pleural effusion fluid from another patient. 
After 3-4 days of culture, cells were washed twice with PBS and fixed in 2% 
paraformaldehyde (Electron Microscope Sciences) in PBS for 15 minutes. Cells were 
washed thrice with PBS and permeabilized in 0.1% Triton X-100 in PBS.  Permeabilized 
cells were incubated with primary antibody in 2% bovine serum albumin overnight at 4 
°C.  Samples were washed twice with PBS containing 0.05% Tween-20, then incubated 
with Alexa-conjugated secondary antibodies (Thermo Fisher) and DAPI (Invitrogen) for 
1 hour of incubation.  Samples were washed twice and stored in PBS at 4 °C.  Imaging 
was performed using an automated high-throughput fluorescence microscope imaging 
system.  
 
Cell culture and drug assays 
Drug assays were performed using Renaissance medium, a fibroblast feeder 
system, or fibroblast feeder system with fibroblasts withdrawn for several passages (as 
indicated in figure legends). Assays were plated in triplicate or quadruplicate in 96-well 
or 384-well plates at 2,000 to 10,000 cells/well. Cells were treated 24-72 hours after 
seeding with drugs (Selleck), and were treated for 72 hours. Viability was determined 
with Cell Titer-Glo (Promega). Percent cell viability was calculated relative to vehicle 




For trametinib and MK2206 drug assays, we used a fibroblast feeder system 
modified from that reported previously63. We plated 800 irradiated mouse embryonic 
fibroblasts and 5,600 never-cultured patient-derived cells (“cancer + fibroblast” assay), 
thawed from frozen viable state, per well in white 384-well plates (quadruplicate). 
Control wells with 800 fibroblasts per well and no cancer cells were also plated 
(“fibroblast-only” assay). Medium included 10 µM Y-2763263. Two to three days later, 
drug was given. Three days after drug addition, viability was measured. Cancer + 
fibroblast signal and associated fibroblast-only signal or cancer + fibroblast minus 
fibroblast (to obtain cancer-only signal) are shown, as indicated in figure legends. All 
data were normalized to DMSO treatment for cancer + fibroblasts or cancer + fibroblast 
minus fibroblast. IC50’s for cancer + fibroblast minus fibroblast were generated in 
GraphPad Prism using regression analysis. Synergy was calculated by Bliss 
independence. A two-sided t-test was performed to compare actual combination response 
with expected. Neratinib assay was done using a similar feeder system as above, except 
that cells were grown without fibroblasts for at least 3-5 passages before assay, so 
fibroblast response was not subtracted out. Salinomycin, UMI-77 and ABT-263 response 
assays were performed without fibroblasts in Renaissance Essential Tumor Medium 
(Cellaria) with 5% FBS, 25 ng/mL cholera toxin (Sigma), and 1% antibiotic/antimycotic 
(Life Technologies); to this was added 20% filtered pleural effusion fluid from another 
patient. Patient Westerns were done in Renaissance medium. For TNF-α and TGF-β 
assays, cells were treated 18 hours with 5 ng/mL TGF-β or 10 ng/mL TNF-α 18, followed 






scRNA-Seq ssGSEA enrichment scores and B2M expression were compared 
between pre- and post-treatment by student’s t-test (two-tailed). Within-sample subclone 
comparisons were done by one-way ANOVA. A two-proportion test was used to 
compare the number of scRNA-Seq cells expressing each gene between pre- and post-
treatment (two-tailed). P-value plots were generated by plotting -1*log10 (p-value) on the 
y-axis against the ranks for these same values (higher ranks for lower p-values). Error 
bars for all drug assays represent standard deviation. 
 
Results and Discussion 
Tumor phenotype evolution in response to chemotherapy 
determined by bulk RNA-Seq 
To determine how phenotypes evolved through treatment in our patients, we first 
performed bulk RNA-Seq on longitudinal cancer samples. We then applied ssGSEA64 to 
this RNA-Seq data to assign each sample an enrichment score for 3,331 gene sets 
(signatures) from the Molecular Signatures Database’s65 C2 collection. To identify 
pathways evolving between longitudinal timepoints, we identified the maximum 
enrichment score change between consecutive timepoint pairs in any patient for each 
signature (Supplementary Fig. 12). This revealed that one EMT signature55 and two 
proliferation-associated signatures (DNA unwinding and G1/S transcription signatures 
from Reactome57) were among the most dramatically changing signatures between 
timepoints. Thus, we further investigated EMT and proliferation signature evolution, as 




Materials and Methods and approach described previously66) due to their recognized 
importance in cancer67, using ASSIGN50 to quantify signature strengths in each sample 
(Fig. 3a). Due to limited material, patient #4’s samples were not analyzed by bulk RNA-
Seq, but were analyzed via single-cell RNA-Seq as discussed later.  
Our analysis revealed increased post-treatment levels of our transcriptional 
signatures for EGFR, K-Ras G12V (Fig. 3a, under “Signature profiling” in purple), IGF-
1R, and Raf (Supplementary Fig. 13), in patients #1 and #2, concomitant with their 
bottleneck events, suggesting that increased receptor tyrosine kinase (RTK) signaling 
may have promoted chemotherapy resistance. Numerous individual RTK genes were 
increased in patients #1 and #2, including EGFR, AXL, PDGFRA, and AXL, among 
others. (See Fig. 3a, right panels under “Individual genes” in purple; see also 
Supplementary Fig. 14 for expression of all 58 RTKs). 
In addition to RTK upregulation, patients #1 and #2 also had increased post-
treatment EMT concomitant with their bottleneck events, as indicated by the 
Anastassiou55 and Jechlinger56 EMT signatures from Molecular Signatures Database (Fig. 
3a, left panels, in green) and individual EMT genes VIM (vimentin), CDH2 (N-cadherin), 
SNAI2 (Snail2), ZEB1, and others (Fig. 3a, right panels, in green and Supplementary Fig. 
15).  
Patient #1 and patient #3 had increased anti-apoptosis after their final treatments.  
For patient #1, this anti-apoptotic signaling was indicated by an increase in our custom 
anti-apoptosis signature consisting of anti-apoptotic Bcl-2 and IAP genes (see Materials 
and Methods) and decrease in our pro-apoptosis Bad signature (Fig. 3a, left, in black). 






Figure 3 | Phenotypic evolution of three breast cancers including increased post-
treatment EMT, RTK, anti-apoptosis, and proliferation properties. ASSIGN 
signature scores for indicated phenotypes for three breast cancer patients (left side) or day 
0-normalized gene RPKM gene expression for indicated genes (right side) based on bulk 
RNA-Seq data of longitudinal samples. RTK-associated data are in purple, EMT in 
green, apoptosis in dark grey, and proliferation in blue. Panel (a) was made in 







and gemcitabine, including BCL2A1 (Bfl-1), BIRC3 (cIAP2), and MCL1 (Fig. 3a, right, 
in black).  For patient #3, the anti-apoptotic signaling was indicated through the CNV 
data (Supplementary Fig. 3c), which showed post-treatment copy loss in regions 
containing extrinsic apoptosis pathway genes CASP8, CASP10, and BID, leading to 
mRNA decrease (Fig. 3a, right, in black). 
Patient #3’s phenotypic evolution, in contrast to patients #1 and #2, did not 
involve increased RTK or EMT phenotypes, notwithstanding the acquired CDH1 (E-
cadherin) mutation, consistent with findings that CDH1 loss-of-function mutations are 
actually associated with lack of EMT in breast cancer68. Instead, this patient’s cancer 
evolved a dramatically increased proliferation phenotype, consistent with our previous 
analysis indicating that proliferation-associated pathways were among the most 
dramatically changing between sequential timepoints (Supplementary Fig. 12), after its 
bottleneck event as shown by increased levels of a cyclin cascade signature and increased 
E2F1 and E2F3 target signatures58,59 from the Molecular Signatures Database (Fig. 3a, 
left, in blue; see Materials and Methods for signature details). Consistent with this, 
numerous individual cell-cycle-associated genes were increased post-treatment in this 
patient, including CCND1 (cyclin D1), CCNB1 (cyclin B1), CCNB2 (cyclin B2), CCNA2 
(cyclin A2), E2F1, E2F2, and MYC (Fig. 3a, right, in blue).  
We confirmed some of these findings by protein analysis of cultured patient #1 
cells. These studies revealed increased post-doxorubicin (day 732) phosphorylation of 
EGFR, Akt, and Erk1/2 by Western blot (Fig. 3b) and increased post-doxorubicin 
vimentin by immunofluorescence (Fig. 3c) and Western blot (Supplementary Fig. 16).                    




acquiring increased RTK and EMT phenotypes over time, while patient #3 acquired 
enhanced proliferation and decreased apoptosis. Interestingly, proliferation score analysis 
indicated that patient #1’s proliferation index also evolved significantly, but mostly in 
response to treatment and not between longitudinal untreated states (Supplementary Fig. 
17). This is in contrast to patient #3, whose proliferation changed dramatically between 
longitudinal untreated states (Fig. 3a). Thus, patient #3’s increased proliferation likely 
represents a true phenotypic change rather than simply being the result of treatment 
cessation. 
The phenotypic changes in patient #1, whose phenotypic evolution was the most 
complex, is summarized in Fig. 3d, as an example of one patient’s step-wise evolution 
through multiple treatments. After each treatment, patient #1 acquired additional 
malignant phenotypes likely promoting drug resistance, including increased ABCB1 
expression (Supplementary Fig. 5a) after paclitaxel, increased RTK and EMT phenotypes 
after doxorubicin, and apoptosis suppression after carboplatin and gemcitabine (Fig. 3d). 
Interestingly, patient #2 likewise acquired RTK and EMT activation concomitantly, 
suggesting these two phenotypes may be coordinately up-regulated in some breast 
cancers after treatment.  
Together, these data highlight the phenotypic plasticity of breast cancer and 
indicate that EMT and RTK activation may be a recurrent feature of drug-resistant breast 
cancer. As we later show, these phenotypes can potentially be targeted to better treat 






Single-cell RNA-Seq reveals post-treatment 
immunosuppressive phenotypes 
 Single-cell RNA-Seq (scRNA-Seq) has several advantages over bulk RNA-Seq,  
including analysis of intratumoral heterogeneity (genetic and non-genetic) and exclusion 
of non-malignant cell contaminants that affect bulk measurements52. We performed 
scRNA-Seq on all four patients, at two timepoints each: patient #1 days 305 and 732, 
patient #2 days 290 and 1320, patient #3 days 249 and 1168, and patient #4 days 4970 
and 5586. We identified cells as normal or cancer based on their copy number profiles 
inferred from scRNA-Seq52 (Supplementary Figs. 18-21; see also Materials and 
Methods). This led to a dataset of 428 individual breast cancer cells from 8 specimens. 
We used t-SNE analysis53 to observe global transcriptional differences between 
malignant cells within and between samples, which showed similarities between samples 
from the same patient (Fig. 4a). We applied the 3,331 C2 signatures to each single cell 
using ssGSEA to obtain enrichment scores for each signature, and ranked each signature 
by its p-value comparing pre- and post-treatment single-cell enrichment scores by 
student’s t-test in each patient (Fig. 4b). This revealed that two broad classes of 
signatures were most dramatically different between pre- and post-treatment samples: (1) 
EMT- and stem-cell-associated69 signatures (red arrows), and (2) immune-associated 
signatures (blue arrows), including TNF-α and antigen presentation signatures. Single-
cell enrichment scores for three highly significant pathways are shown in Fig. 4c, along 
with a signature for all 58 RTKs62, which confirmed increased post-treatment EMT and 
RTK phenotypes, and revealed that TNF-α signaling and antigen presentation decrease  




Figure 4 | Single-cell RNA-Seq of pre- and post-treatment breast cancers reveals 
increased immune-avoidance, EMT, and RTK phenotypes. (a) t-SNE analysis of 428 
individual cells’ expression profiles from pre- and post-treatment breast cancer samples 
from four patients. (b) Plots of p-values (t-test-derived) comparing ssGSEA enrichment 
scores for 3,331 C2 signatures between pre- and post-treatment single cells in each 
patient. x-axis, p-value ranks (higher ranks are more significant); y-axis, -log10(p-value). 
Red arrows, EMT- and stem cell-related signatures; blue arrows, immune-related 
signatures. (c) ssGSEA enrichment score (relative to pre-treatment average) violin plots 
for single cells in each sample for indicated signatures. Each point represents a single 
cell. p-values are by student’s t-test. (d) Expression of indicated genes by scRNA-Seq (x-
axis) in individual cells (y-axis) with percent of cells expressing each gene or average 
expression indicated below in grey bars. p-values are by two-sample proportion test. x-
axis scales all begin at zero (left) and are the same within patients for each gene. (e) 
Western blot of indicated cells treated for 18 hours with TGF-β (5 ng/mL) or TNF-α (10 














avoid immune responses, as loss of both TNF-α signaling70,71 and antigen presentation72 
are likely to suppress basal or treatment-induced immune responses. To identify 
individual genes driving these phenotypes, we statistically analyzed the proportion of 
single cells expressing each gene between pre- and post-treatment samples in each patient 
(Supplementary Fig. 22). This revealed, in multiple patients, significant 
differences between pre- and post-treatment proportions of cells expressing the EMT- 
and stem cell-associated genes VIM (vimentin56) and ID473,74; the RTK genes AXL and 
ROR175; the TNF-α pathway genes TNF (TNF-α) and TNFAIP376; and the antigen 
processing gene TAP177 (Fig. 4d). EGFR also increased in post-treatment cells by 
scRNA-Seq (Supplementary Fig. 23), consistent with bulk RNA-Seq (Fig. 3a, b). In 
addition, the essential antigen presentation gene B2M, encoding the β2-microglobulin 
subunit required for HLA class I cell-surface expression78, was present in all cells but had 
statistically decreased expression by student’s t-test in 3 of 4 patients (Fig. 4d, top-right).  
Given concurrent EMT increase and loss of TNF-α and antigen presentation after 
treatment in some patients, we hypothesized that EMT may suppress antigen presentation 
and that TNF-α may promote antigen presentation. To test this hypothesis, we treated 
four breast cancer cell lines with the EMT promoter TGF-β79 or with TNF-α and 
measured β2-microglobulin by Western blot. While TGF-β had little effect, TNF-α 
substantially increased β2-microglobulin levels in two cell lines (Fig. 4e). This indicates 
that TNF-α, in addition to promoting T cell activation, may also increase the 
susceptibility of cancer cells to cytotoxic T cells by increasing antigen presentation. This 
also suggests that decreased post-treatment B2M levels (Fig. 4d) may be due to 




may have been less apparent in bulk RNA-Seq due to dramatically different (often 
increased) expression of immune-related genes in normal cells, such as fibroblasts, 
present in the cancer milieu (Supplementary Fig. 24).  
 
Single-cell RNA-Seq reveals pre-treatment EMT, RTK, and  
immune-avoidance phenotypes in survivor subclones 
Our analysis shows that cancers acquire additional malignant phenotypes in 
response to therapy. This likely occurs through (1) genetic selection for subclones with 
these features and/or (2) drug-induced changes. To test whether acquired phenotypes 
were present before treatment in survivor subclones (scenario #1), we assigned pre-
treatment single cells to subclones identified using DNA sequencing. To assign each cell 
to a subclone, we used a combination of CNV inferred from scRNA-Seq52 data and 
analysis of subclone-defining point mutations with scRNA-Seq coverage (Supplementary 
Figs. 18-21; “*” indicates relevant CNVs). CNVs that were partially present before 
treatment, and subsequently increased post-treatment, were assumed to represent a pre-
treatment survivor subclone, while those that were partially present pre-treatment but 
later disappeared were assumed to represent a disappearing subclone. Cells were 
assigned to either survivor or disappearing subclones based on these CNVs; subclone 
assignment was further refined by identification of rare cells with coverage of subclone-
defining mutations (Supplementary Fig. 18). 
To identify signatures significant different between pre-treatment subclones, we 
compared ssGSEA enrichment scores for 3,331 C2 signatures, plus the all-58 RTKs  




ANOVA for each patient (Fig. 5a). This revealed differences in antigen presentation and 
RTK signatures between subclones in patient #1 (Fig. 5a and 5b). The patient #1 pre-  
treatment survivor subclone that gave rise to the post-treatment bottleneck subclone had 
decreased antigen presentation and increased RTK expression compared to other 
subclones, suggesting that these phenotypes were genetic and pre-existed before 
treatment. Thus, in patient #1, several pre-treatment subclones varied in their antigen 
presentation and RTK levels (Fig. 5c). A subclone with decreased antigen presentation 
and increased RTK expression (light-orange) may have had a selective advantage and 
thus gave rise to the post-treatment bottleneck subclone (dark-orange), which had 
additionally evolved increased EMT (Fig. 5c). Further, the patient #2 survivor subclone 
also had a partially increased EMT- and actin cytoskeleton-associated gene expression, 
compared to the disappearing subclone, while post-treatment EMT levels increased 
further (Fig. 5d), although assignment of single cells to subclones in this patient was less 
clear due to dependence on a single CNV (on chromosome 20). The patient #3 survivor 
subclone possessed a diminished epithelial differentitation phenotype and an enhanced 
PI3K signature that was apparently carried into its descendant subclone after treatment 
(Fig. 5e). Finally, the patient #4 survivor subclone possessed decreased expression of 
transcriptional targets of the HOXA5 tumor suppressor80, decreased TNF signaling, 
decreased antigen presentation, and increased RTK expression, which were likewise 
present in its descendant post-treatment subclones (Fig. 5f). These data indicate that the 
post-treatment RTK, EMT, and immune-avoidance phenotypes pre-existed before 
treatment in a genetically defined subclone in some cases, and may have been selected 




Figure 5 | Pre-existence of post-treatment phenotypes in pre-treatment survivor 
subclones. (a) Plots of p-values (one-way ANOVA) comparing scRNA-Seq ssGSEA 
enrichment scores for 3,331 C2 signatures, plus the receptor tyrosine kinases (all-58) 
signature and our anti-apoptosis signature, between subclones in each patient’s pre-
treatment sample. x-axis, p-value ranks (higher ranks are more significant); y-axis, -
log10(p-value). (b) ssGSEA enrichment scores (or individual gene expression levels) for 
single cells in each pre-treatment subclone, with post-treatment cells shown for 
comparison. Each dot represents a single cell. p-values are by student’s t-test. Subclones 
correspond to those shown in Fig. 2a. “X” indicates disappearing subclone while “surv” 
indicates the subclone giving rise to the post-treatment sample. (c) Schematic showing 
subclonal phenotypic heterogeneity in pre-treatment patient #1 cells. (d) As in (b) but for 










Targeting evolving phenotypes in tumors using adaptive treatment strategies 
 It is important to identify adaptive therapeutic regimens that effectively target the 
dynamic, heterogeneous nature of breast cancer. Even where it is not possible to target a 
specific mutation, we can match treatments to altered cellular phenotypes. Because RTK 
activation and the EMT phenotype increased after treatment-induced bottleneck events in 
three patients (Figs. 3a, 4c), we hypothesized that these post-treatment cells may have 
acquired sensitivity to drugs targeting these phenotypes. To test this hypothesis, we 
compared the response of patient #1 pre- and post-doxorubicin cancer cells (day 305 and 
732) to inhibitors of MEK and AKT (trametinib81 and MK220682), two important RTK 
effectors62, and the HER/ErbB family (neratinib83), given this patient’s early 
classification as HER2+ per clinicians.  We also tested the EMT and cancer stem cell 
inhibitor salinomycin69,84, due to enhanced post-doxorubicin EMT. Patient-derived breast 
cancer cells were grown using a modified fibroblast feeder approach63 and other 
approaches (see Materials and Methods).  
Post-doxorubicin patient #1 cells were moderately more sensitive to MEK and 
AKT inhibitors than pre-doxorubicin cells (Fig. 6a). We also tested these drugs in 
combination due to redundancy between PI3K and MAPK signaling85–87. Remarkably, 
post-doxorubicin cells were dramatically more sensitive to the equimolar combination of 
trametinib and MK2206 (Fig. 6b, top), with a combined IC50 of 4.37 µM in the post- 
doxorubicin cells and an unmet IC50 in the pre-doxorubicin cells due to lack of response 
at doses tested (see also Supplementary Fig. 25a). The combination was synergistic at 
3.125 µM (Fig. 6b, bottom) and 6.25 µM (Supplementary Fig. 25b), using Bliss 





Figure 6 | Acquired sensitivity to drugs targeting post-chemotherapy phenotypes. (a) 
Drug response assay comparing pre- and post-doxorubicin patient #1 cancer cells’ 
sensitivity to drugs after 3-day treatment (fibroblast feeder system; CellTiter-Glo was 
used). (b) Indicated cells were treated with equimolar doses of trametinib and MK2206 
for 3 days, followed by CellTiter-Glo (top); synergy analysis of 3.125 µM doses of these 
drugs (bottom). Expected is by Bliss independence; p-value is by student's t-test. 
Fibroblast feeder system was used and fibroblast signal was subtracted out in (a) and (b). 
(c) Drug response assay comparing patient #1 pre- and post-carboplatin and gemcitabine 














salinomycin showed equivalent responses between pre- and post-doxorubicin cells 
(Supplementary Fig. 26a). These data suggest that enhanced RTK signaling post-
doxorubicin (Fig. 3a, b) induced increased dependency on downstream PI3K and MAPK 
signaling. We also found that patient tumor cells taken post-carboplatin and gemcitabine, 
while not more sensitive to Bcl-2 family inhibitors (Supplementary Fig. 26b) 
notwithstanding increased Bcl-2 family gene expression (Fig. 3a), were more sensitive to 
salinomycin than pre-treatment cells (Fig. 6c). This response correlates with increased 
EMT, including decreased E-cadherin (CDH1), after carboplatin and gemcitabine (Fig. 
3a, Supplementary Fig. 15). Interestingly, there was no differential salinomycin response 
between pre- and post-doxorubicin timepoints, perhaps due to the cells’ dependence on 
growth receptor signaling after doxorubicin (Supplementary Fig. 26a).  
These findings indicate that the development of disease refractory to one 
treatment may be associated with enhanced sensitivity to an alternative treatment 
targeting post-treatment emerging phenotypes. This approach can potentially be 
employed in drug-resistant cancers to improve outcomes.  
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Supplementary Figure 12 | Identification of dramatically evolving signatures in bulk 
RNA-Seq data from three breast cancers. ssGSEA enrichment scores were determined 
for bulk RNA-Seq samples for patients #1-#3 for 3,331 C2 signatures, and the maximum 
absolute value difference between consecutive timepoints from any patient were plotted 





Supplementary Figure 13 | Additional RTK signatures increasing in two breast 
cancer patients after treatment. ASSIGN signature scores for indicated pathways for 
two breast cancer patients. Expression signatures were generated by experimentally 
overexpressing indicated genes in human mammary epithelial cells, followed by RNA-
Seq to identify genes indicative of pathway activation. Made in conjunction with and 










Supplementary Figure 14 | Evolution of RTK gene expression in three breast cancer 
patients. Heatmaps showing log2 fold change expression from day 0 (RPKM expression 
values) for all 58 receptor tyrosine kinases over time in breast cancer patients #1 (left), #2 
(middle), and right (#3). RTKs are sorted by fold-change expression from day 0 in the 





Supplementary Figure 15 | Evolution of EMT-associated gene expression in three 
breast cancer patients. Day 0-normalized expression (RNA-Seq RPKM values) for 
EMT-associated transcription factors and other genes for patients #1 (top), #2 (middle), 
and #3 (bottom) over time with drug treatment indicated in grey. See Fig. 2 legend for 





Supplementary Figure 16 | Vimentin is increased in patient #1 cells per Western 
blot. Western blot of cultured patient #1 pre- (day 305) and post-doxorubicin (day 732) 
cells using same lysate as in Fig. 3b and same Erk1/2 loading control. Renaissance 



















Supplementary Figure 17 | Changes in proliferation over time in patient #1. (a) 
Expression of the gene encoding Ki67 per RNA-Seq (RPKM) over time. (b) Proliferation 
score over time in patient #1. (b) was made in conjunction with and used with permission 








Supplementary Figure 18 | Copy number and subclones inferred from single-cell 
RNA-Seq of patient #1. scRNA-Seq was performed on pre- and post-treatment cells 
from patient #1 and copy number was inferred and corroborated with bulk DNA-Seq-
based copy for each gene. Subclones were identified using CNVs and subclone-defining 
point mutations as described in text and Methods. * indicates CNVs aiding with subclone 
identification. ? indicates cells with unclear subclone identity. Subclones assigned 




Supplementary Figure 19 | Copy number and subclones inferred from single-cell 
RNA-Seq of patient #2. scRNA-Seq was performed on pre- and post-treatment cells 
from patient #2 and copy number was inferred and corroborated with bulk DNA-Seq-
based copy for each gene. Subclones were identified using CNV (chromosome 20q loss) 
as described in text and Methods. * indicates CNV aiding with subclone identification. ? 
indicates cells with unclear subclone identity (equivocal 20q status). Subclones assigned 




Supplementary Figure 20 | Copy number and subclones inferred from single-cell 
RNA-Seq of patient #3. scRNA-Seq was performed on pre- and post-treatment cells 
from patient #3 and copy number was inferred and corroborated with bulk DNA-Seq-
based copy for each gene. Subclones were identified using CNVs as described in text and 
Methods. * indicates CNVs aiding with subclone identification. Subclones assigned 





Supplementary Figure 21 | Copy number and subclones inferred from single-cell 
RNA-Seq of patient #4. scRNA-Seq was performed on pre- and post-treatment cells 
from patient #4 and copy number was inferred and corroborated with bulk DNA-Seq-
based copy for each gene. Subclones were identified using CNVs as described in text and 
Methods. * indicates CNVs aiding with subclone identification. Subclones assigned 




Supplementary Figure 22 | Identification of genes differentially expressed between 
pre- and post-treatment samples by single-cell RNA-Seq. scRNA-Seq was performed 
on pre- and post-treatment samples from patients #1-#4 and a two-sample proportion test 
was performed on each patient for each gene to compare the proportion of cells in pre- 
vs. post-treatment samples expressing each gene. p-value ranks (x-axis; higher rank 
indicates higher significances) were plotted against  -log10 (p-value) for each gene 





Supplementary Figure 23 | EGFR is increased after treatment in two out of four 
breast cancer patients by single-cell RNA-Seq. EGFR expression (y-axis) was plotted 
for each single cell in each patient and a two-sample proportion test was performed to 
compare the proportion of cells in pre- vs. post-treatment cells expressing EGFR (see p-




Supplementary Figure 24 | Detection of EMT, RTK, and immune-avoidance 
phenotypes in bulk RNA-Seq may be hampered by normal cell contaminants. 
scRNA-Seq was performed on pre- and post-treatment samples from four patients and 
cells were identified as normal or cancer based on copy profiles (Supplementary Figs. 18-
21). Expression of the 8 indicated genes, found to be differentially expressed between 
pre- and post-treatment cancer samples, is shown in both normal and cancer populations 




Supplementary Figure 25 | Acquired sensitivity to combined MEK and Akt 
inhibition in post-doxorubicin patient #1 cells. (a) Pre- and post-doxorubicin patient #1 
cells grown on fibroblasts (or fibroblasts only with no cancer cells) were treated with 
equimolar doses of indicated drugs and subjected to CellTiter-Glo assay after 3 days of 
treatment. Data are normalized to DMSO control mean (= 100%) for cancer + fibroblasts 
wells. Fibroblast-only wells were normalized to pre-dox (grey triangles) or post-dox (red 
triangles) cancer + fibroblasts DMSO control mean. Dox, liposomal doxorubicin. Cells 
were from day 305 (pre-dox) or day 732 (post-dox). (b) Synergy analysis of 6.25 µM 
dose of combined trametinib and MK2206 in pre- and post-doxorubicin cells. Expected is 
by Bliss independence; p-value is by student's t-test. (Fibroblast-only signal was 





Supplementary Figure 26 | Lack of acquired sensitivity to salinomycin and neratinib 
in patient #1 post-doxorubicin cells and to Bcl-2 family inhibition in post-
carboplatin cells. (a) Cultured pre- (day 305) and post-doxorubicin (day 732) patient #1 
cells were treated for 72 hours with indicated drug doses, followed by viability 
measurement with CellTiter-Glo. Data are normalized to DMSO treatment mean (= 
100%). Salinomycin assay was done with Renaissance medium while neratinib assay was 
done with fibroblast feeder system with fibroblasts withdrawn (see Methods). (b) 
Cultured pre- (day 721) and post-carboplatin + gemcitabine (day 858) cells were treated 
for 72 hours with indicated drug doses, followed by viability measurement with 
CellTiter-Glo. Assays were done in Renaissance medium. Made in conjunction with and 












SUMMARY AND PERSPECTIVES 
 
 These findings strengthen our understanding of the genetic and phenotypic 
evolution of breast cancer using an analytical approach of greater depth than any 
performed previously, to our knowledge, on longitudinal breast cancer samples. They 
identify specific ABCB1 fusions and BRCA2 reversions not previously reported in breast 
cancer samples, and reveal EMT, RTK activation, and immune-avoidance phenotypes as 
potential mechanisms providing selective advantage after treatment. Further, these 
phenotypes likely pre-exist, at least in part, in some pre-treatment subclones, and thus 
have may have a genetic basis. Drug treatment assays indicate that these phenotypes can 
suggest drugs to which the cancer has acquired sensitivity, concomitant with their 
acquired resistance to the current therapy.  
Further follow-up on these results may lead to improved treatment options for 
patients. For example, better approaches are needed to target ABCB1 in drug-resistant 
cancers. Immune-activating drugs may be effective, in combination with chemotherapy, 
in preventing acquisition of the immune-avoidance phenotype. 
 In summary, an improved understanding of the post-treatment acquired genetic 
and phenotypic changes may lead to more effective treatments for breast cancer, and lead 
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